Targeted Oncology Staff

Participants of a live, virtual case-based event discussed different scenarios for treatment of a patient with previously untreated clear cell renal cell carcinoma. Vote in the polls on what you would have chosen if this was your patient.

During a Targeted Oncology case-based roundtable event, Ajay Kandra, MD, discussed with participants the challenges and treatment options for a patient with extensive-stage small cell lung cancer.

During a Targeted Oncology case-based roundtable event, Pallawi Torka, MD, discussed with participants when to consider a patient for chimeric antigen receptor T-cell therapy and what alternative treatments to use for a patient with relapsed/refractory diffuse large B-cell lymphoma.

During a Targeted Oncology case-based roundtable event, Daniel R. Couriel, MD, MS, MBA, discussed how to predict risk of acute graft-vs-host-disease and manage its effects on patients with hematologic malignancies.

During a Targeted Oncology case-based roundtable event, Ghassan K. Abou-Alfa, MD, MBA, discussed the case of a patient with hepatocellular carcinoma whose comorbidities impacted the choice of treatment.

During a Targeted Oncology case-based roundtable event, Alison K. Conlin, MD, discussed with participants their choice of first- and second-line therapy for a patient with triple-negative breast cancer.

During a Targeted Oncology case-based roundtable event, Thomas Hutson, DO, PharmD, discussed the most recent data supporting immune checkpoint inhibitor plus tyrosine kinase inhibitor combinations for frontline treatment of patients with renal cell carcinoma.

During a live virtual event, Thomas Hutson, DO, PharmD, discussed the outcomes of the CLEAR trial of lenvatinib plus pembrolizumab for patients with advanced renal cell carcinoma.

During a Targeted Oncology case-based roundtable event, Alan H. Bryce, MD, discussed the case of a patient with high-volume, hormone-naive metastatic prostate cancer.

During a Targeted Oncology case-based event, Jason Luke, MD, and Laura K. Ferris, MD, PhD, discussed treatment for a patient with basal cell carcinoma.

During a Targeted Oncology case-based roundtable event, Rafael Santana-Davila, MD, discussed the data supporting the use of immunotherapy for patients with extensive-stage small cell lung cancer.

During a Targeted Oncology case-based roundtable event, Peter Forsberg, MD and Robert M. Rifkin, MD, FACP, discussed the trials supporting the use of BCMA-targeted agents for relapsed/refractory multiple myeloma.

During a Targeted Oncology case-based roundtable event, Angela G. Fleischman, MD, PhD, discussed how to approach treatment of a 68-year-old patients with myelofibrosis.

Approval has been granted by the FDA to betibeglogene autotemcel for the treatment of patients with beta-thalassemia based on multiple phase 3 studies.

During a live virtual event, Roby A. Thomas, MD, discussed the tolerability of androgen receptor therapy and personal experiences with treatment of patients with metastatic castration-sensitive prostate cancer. This is the second of 2 articles based on this event.

During a live virtual event, Elizabeth Ann Mittendorf, MD, PhD, discussed the case of a patient with triple-negative breast cancer whose disease progressed following adjuvant dose-dense doxorubicin plus cyclophosphamide with paclitaxel, then frontline gemcitabine and carboplatin. This is the second of 2 articles based on this live event.

During a live virtual event, Robert Dreicer, MD, MS, discussed the use of cabazitaxel and 177-lutetium-PSMA-617 for patients with metastatic castration-resistant prostate cancer.

During a live virtual event, Benjamin P. Levy, MD, discussed the results of the IMpower 133 and CASPIAN trials of immunotherapy for patients with extensive-stage small cell lung cancer.

During a Targeted Oncology case-based roundtable event, Christine Bestvina, MD, discussed the outcomes of clinical trials of the EGFR exon 20-targeted agents amivantamab and mobocertinib with participants. This is the second of 2 articles based on this event.

During a Targeted Oncology live virtual event, Caitlin Costello, MD, discussed treatment of a patient who previously received systemic therapy and autologous stem cell transplant for multiple myeloma. This is the second of 2 articles based on this event.

During a live virtual event, Martin F. Dietrich, MD, PhD, discussed the results of the EMPOWER-Lung 1 and EMPOWER-Lung 3 trials of cemiplimab for non–small cell lung cancer.

During a Targeted Oncology case-based roundtable event, Dipenkumar Modi, MD, and participants discussed the leading later-line therapy options for patients with diffuse large B-cell lymphoma.

During a live virtual event, Thomas Hutson, MD, PharmD, discussed the 4 frontline combination regimens including immunotherapies and tyrosine kinase inhibitors. This is the first of 2 articles based on this live event.

At a live virtual event, Devika Das, MD, discussed the use of immunotherapy for patients with extensive stage-small cell lung cancer (ES-SCLC) and for patients with non–small cell lung cancer.

During a Targeted Oncology case-based roundtable event, Hana F. Safah, MD, discussed risk factors for acute graft-versus-host disease and data supporting treatment for steroid-refractory disease.

During a Targeted Oncology case-based roundtable event, Chung-Han Lee, MD, PhD, discussed the approved frontline regimens for patients with advanced clear cell renal cell carcinoma.

During separate virtual live events, Sandy T. Liu, MD, and Moshe Ornstein, MD, MA, discussed what treatment they would choose for a patient with clear cell renal cell carcinoma and the trial data available in this setting.

During a Targeted Oncology case-based roundtable event, Elizabeth Ann Mittendorf, MD, discussed with participants their choice of treatment after progression for a patient with triple-negative breast cancer treated with adjuvant dose-dense doxorubicin plus cyclophosphamide with paclitaxel. This is the first of 2 articles based on this event.

During a Targeted Oncology case-based roundtable event, Sheela Tejwani, MD, discussed therapy options for a patient with metastatic castration-sensitive prostate cancer.

During a Targeted Oncology case-based roundtable event, Matthew Powell, MD, discussed trials supporting the use of the PARP inhibitors niraparib and olaparib for patients with BRCA-positive ovarian cancer.